Related Experiment Video

Updated: Apr 14, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

3.3K

The ubiquitin-proteasome pathway an emerging anticancer strategy for therapeutics: a patent analysis

Chakresh K Jain1, Shivam Arora, Aparna Khanna

  • 1Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector-62, Noida- 201307, Uttar Pradesh, India. ckj522@yahoo.com.

Recent Patents on Anti-Cancer Drug Discovery
|April 17, 2015
PubMed

Insights

The ubiquitin-proteasome pathway degrades intracellular proteins and is crucial for cell cycle regulation. Targeting this pathway offers promising new anti-cancer strategies, with recent patents highlighting its therapeutic potential.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The ubiquitin-proteasome pathway (UPP) is a conserved, ATP-dependent non-lysosomal proteolytic system essential for cellular protein homeostasis.
  • Ubiquitination, regulated by E3 ligases and phosphorylation, targets proteins in the cytosol and nucleus for degradation.
  • Dysregulation of the UPP is implicated in diseases such as cancer and inflammation.

Purpose of the Study:

  • To review the emerging prospects and importance of the ubiquitin-proteasome pathway as an evolving anticancer strategy.
  • To discuss current challenges in drug discovery related to UPP-targeted cancer therapeutics.

Main Methods:

  • Literature review focusing on the ubiquitin-proteasome pathway's role in cancer.
  • Analysis of recent patents concerning cancer diagnosis and therapeutics.
  • Discussion of apoptosis induction mechanisms, including TNF-related apoptosis-inducing ligand (TRAIL) signaling.

Main Results:

  • The UPP plays a critical role in regulating cell cycle proteins, making it a viable target for anti-cancer therapies.
  • Dysfunction in the UPP is linked to oncogenesis and inflammatory processes.
  • TRAIL-receptor interactions can trigger apoptosis, a key mechanism in cancer cell death.

Conclusions:

  • The ubiquitin-proteasome pathway represents a significant and evolving target for novel anti-cancer strategies.
  • Addressing challenges in drug discovery for UPP-targeted therapies is crucial for advancing cancer treatment.
  • Understanding UPP regulation and its link to apoptosis is key for developing effective cancer diagnostics and therapeutics.

More Related Videos

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

6.2K
Ubiquitin Chain Analysis by Parallel Reaction Monitoring08:33

Ubiquitin Chain Analysis by Parallel Reaction Monitoring

Published on: June 17, 2020

4.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.7K
The Proteasome02:18

The Proteasome

5.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K